• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Interview Intersection: Expert Interviews From March 2024


Dermatology Times is recapping our top expert interviews from the month of March.

An Inside Look in the Development of CGB-500 For Atopic Dermatitis Treatment

Nitin Joshi, PhD, shared CAGE Bio’s development of CGB-500 and why phase 2 EASI scores have the company’s scientific advisory board optimistic.

Valisure's David Light Unpacks Benzene Findings, Stability Testing, and Discourse

Following the announcement of Valisure's findings related to benzene and benzoyl peroxide acne products, Dermatology Times spoke with David Light, co-founder and president of the laboratory behind the report, to discuss the findings, the role of stability testing requirements, and quelling fear-filled online discourse.

Celebrating Women in Dermatology

Today is International Women's Day. Dermatology Times spoke with 5 women clinicians in the field to discuss the influences and advice that brought them to where they are today.

Combining Surgical Precision With Immunological Innovation in Vitiligo Treatment

Maggi Ahmed, MD, PhD, demonstrated superior pigmentation outcomes and reduced CD8+ T cell numbers in her recent research results.

Nicole A. Negbenebor, MD: Uplifting Women Clinicians

In celebration of Women's History Month and today, which is International Women's Day, dermatologist Nicole Negbenebor, MD, discusses her journey in the dermatology space and provides advice for young women and girls aspiring to enter the medical field.

Navigating the Path to Equity: Insights from Aletha Maybank, MD, MPH

"We cannot do health equity outside of an institution unless we figure out how to get our own house in order," the AMA leader said.

Conquering the Dermatology Board Exam: Tips From Raj Chovatiya, MD, PhD

Chovatiya acknowledged the common sentiment among residents who, despite dedicating significant time to studying and working during residency, may feel unprepared.

AAD is More Than Just a Conference

Neal Bhatia, MD, shares his insights on successfully navigating AAD and his session highlights on office politics.

Peter Lio, MD, FAAD: Navigating Dietary Triggers in Urticaria and Atopic Dermatitis

Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."

Acne and Rosacea Pearls With Jim Del Rosso, DO, FAAD

The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.

Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.

Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.

Adam Friedman, MD, FAAD: Exploring the Utilization of Immunomodulators as Therapeutic Interventions in Chronic Spontaneous Urticaria

In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.

Anticipated FDA Approval of Bimekizumab for HS: Insights From Investigator Christopher Sayed, MD

The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.

Trends in Cosmeceuticals and Nutraceuticals: Exosomes and Adaptogens Take Center Stage

Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.

Alan Mendelsohn, MD, Shares Insights Into Congenital Ichthyosis Patient Care and the Development of TMB-001

The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.

How is Artificial Intelligence Growing Up?

Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.

Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients

Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.

Johnson & Johnson Reveals Promising Results for JNJ-2113 in FRONTIER 2 Study

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD

Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.

Topics and Pearls

  • Disease states such as atopic dermatitis, vitiligo, acne, rosacea, hidradenitis suppurativa, chronic spontaneous urticaria, psoriasis, hair loss
  • Aesthetic treatments, innovations, and methods
  • Practice management and clinician advice
  • Late-breaking clinical research
  • Drugs in development and anticipated approvals
  • Uplifting women and patients of special populations to achieve equitable care
  • Benzene and benzoyl peroxide

Late-Breaking Data: Long-Term Safety and Efficacy of Delgocitinib Cream for Chronic Hand Eczema

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

Navigating Finances in Dermatology: Top 5 Considerations for Dermatologists

In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.

Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

Richard Gallo, MD, PhD: Updates on Understanding the Pathophysiology of Acne

Gallo presented pearls on the pathophysiology of acne and how newer studies have changed acne treatment methodologies at AAD 2024.

Navigating Delusional Infestations in Dermatology

Jenny Murase, MD, said the average dermatologist manages 2-3 patients with delusional infestations every 5 years. Learn what to expect and how to manage it with empathy.

Peter Lio, MD, FAAD: Minimizing Pain and Addressing Systemic Malignancy With Alternative Therapies

Lio spoke with Dermatology Times to discuss his sessions at AAD 2024, including addressing systemic malignancies with alternative or adjunctive therapies and the importance of minimizing pain in dermatology procedures.

Sharing Innovations in Psoriasis Biologics and Uplifting Women in Dermatology

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.

Jill Waibel, MD, FAAD: Innovations in Laser Modalities for the Treatment of Scars

Waibel shared pearls in laser therapy and other scar treatment modalities in her talks at the American Academy of Dermatology Annual Meeting.

Science Behind OTC Products to Enhance Care for Atopic Dermatitis, Acne, and Sun Protection

Menes Kizoulis shared key highlights from the research conducted alongside leading dermatologists, like Alan Irvine, MD, DSc, and Patricia Farris, MD, MS.

Addressing Antibiotic Stewardship and Acne Guidelines at AAD

Naiem Issa, MD, PhD, emphasized the importance of increased awareness regarding antibiotic stewardship among dermatologists, as well as the recently updated acne guidelines.

Lisa Swanson, MD, FAAD: Clinical Pearls and Updates for Pediatric Dermatology

Swanson shared updates and a look ahead and what's in store for the field of pediatric dermatology.

Late-Breaking Data: Povorcitinib Significantly Improves Itch and Lesions in Prurigo Nodularis

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.

Cheri Frey, MD, FAAD: Exploring Cosmeceutical Ingredients and Their Role in Skin Health

Frey discussed the role of various cosmeceuticals and ingredients in benefitting the skin health of patients, as well as insights into pairing OTC products with Rx.

Red, Itchy, And AD Until Proven Otherwise

Raj Chovatiya, MD, PhD, delves into the conditions that could be red, itchy, and not atopic dermatitis. He explains the importance of knowing characteristics for various inflammatory conditions.

Catching Up With Karan Lal, DO, MS FAAD

In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.

What’s New in Hair Loss Therapies and Exosomes?

Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.

How Can Patients Benefit From New Device, TruFacial?

Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.

Q&A: Late-Breaking REMIX-1 and REMIX-2 Data Demonstrated Efficacy of Remibrutinib in Chronic Spontaneous Urticaria

Allergist immunologist Giselle Mosnaim, MD, recently spoke with Dermatology Times to discuss late-breaking phase 3 REMIX-1 and REMIX-2 data presented at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Zoe Diana Draelos, MD, Offers Perspectives on Benzene and Benzoyl Peroxide

With 30 years of clinical dermatology research under her belt, Draelos responds to recent benzene and BPO news in this Q&A.

Robert Den, MD: Exploring the Potential of Alpha DaRT in Skin Cancer

Den, the chief medical officer of Alpha Tau, discusses the alpha particle-emitting atom treatment and its ability to target cancer cells without harming healthy tissue.

Consensus, Concern, and Commentary: Clinicians Share Thoughts on 'The BPO Bombshell'

We spoke with several dermatology experts to gauge their thoughts on Valisure's recent findings of benzene in benzoyl peroxide products--as well as what actions they plan to take moving forward.

Women's Dermatologic Society: New President Shares Hopes for Enduring Positive Change on Organization and Dermatology

Dermatology Times recently spoke with Latanya Benjamin, MD, FAAD, FAAP, the newly-appointed president of the WDS, to discuss her hopes and goals for her presidency.

Kim Papp, MD, PhD, FRCPC: Exploring the Potential of ESK-001 in Plaque Psoriasis

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations

Spizuoco shares pearls from her sessions, "Infectious Diseases: The Story Behind STDs," and "Everything You Need to Know About Dermatopathology and the Dermatopathologist," from the Diversity in Dermatology conference.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.